Sai Parenterals Releases Q4 & FY26 Earnings Call Transcript
Sai Parenterals released its Q4 & FY26 earnings call transcript. FY26 consolidated revenue grew 133% to ₹381 crore. The company targets ₹750 crore revenue for FY27 with a 17% EBITDA margin. A ₹440 crore capex program is underway, including an Australian facility expansion and Indian upgrades, expected to contribute from FY28.
The announcement provides detailed financial results, strategic updates on a significant acquisition, and future growth projections, which are crucial for investors and analysts.
The company reported strong growth in revenue and profit, highlighted a successful acquisition, and provided positive future guidance. The transcript details strategic initiatives and financial performance positively.
Sai Parenterals Limited has disclosed the transcript of its earnings conference call held on May 27, 2026. The call, which covered the company's performance for the fourth quarter and full fiscal year 2026, highlighted a transformational year marked by a successful IPO and the acquisition of Australia-based Noumed Pharmaceuticals.
This acquisition is a significant strategic milestone, transforming Sai Parenterals into a global IP-led platform. It expands capabilities in product development, manufacturing, regulatory filings, and commercialization. The integration of Noumed is expected to accelerate product launch timelines and improve margins through vertical integration, with the Australian manufacturing facility set to become operational in Q4 FY27.
For fiscal year 2026, the standalone business reported revenues of ₹162 crore, a 30% increase, with EBITDA at ₹33 crore (21% of revenue) and PAT growing 64% to ₹17 crore. On a consolidated basis, following the Noumed acquisition (effective November 12, 2025), revenues stood at ₹381 crore, a 133% growth, with EBITDA at ₹47 crore (12.3% of revenue). Q4 FY26 consolidated revenue was ₹198 crore with EBITDA of ₹29 crore (14.6% of revenue).
The company is executing a ₹440 crore growth capex program, including EU GMP upgrades in India (₹110 crore from IPO proceeds) and establishing an R&D center (₹15 crore from IPO proceeds). The Australian facility expansion involves a total capex of AUD 53 million (₹311 crore), with AUD 20 million granted by the Australian government and the balance funded by debt and internal accruals.
For FY27, Sai Parenterals is targeting revenue of ₹750 crore with an EBITDA margin of 17%. The full impact of the capex investments is expected in FY28. The company's balance sheet has been strengthened post-IPO, with total debt at ₹319 crore as of March 2026. FY27 is anticipated to be the peak year for debt, with levels expected to decline from FY28 onwards.
What to do with a filing like this
Sai Parenterals Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sai Parenterals Limited. Read the original for the full detail.